Real-Word Effectiveness of 8, 12 and 24 Weeks Ledipasvir (LDV)/Sofosbuvir (SOF)-Based Therapy for Hepatitis C Virus (HCV) Genotype 1: Analysis in a Large Integrated Health Care System

Lai, Jennifer B.; Witt, Maxwell A.; Witt, David J.

doi:10.1016/s0168-8278(16)01517-8

Cited by 3 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, four studies were removed due to potential for overlap (http://onlinelibrary.wiley.com/doi/10.1002/hep.29005/suppinfo). This led to selection of six studies for inclusion, of which one was a published manuscript and the remainder were published abstracts . A total of 5,637 cases were identified, with the study sample size varying from 90 to 1,981 patients.…”

Section: Resultsmentioning

confidence: 99%

“… Forest plot comparing RR for relapse between 8 weeks' and 12 weeks' duration of LDV/SOF treatment. Studies are as follows: Afdhal et al, Backus et al, Buggisch et al, Crespo et al, Gill et al, and Lai et al…”

Section: Resultsmentioning

confidence: 99%

“…Forest plot comparing RR for relapse between 8 weeks' and 12 weeks' duration of LDV/SOF treatment. Studies are as follows: Afdhal et al, (12) Backus et al, (13) Buggisch et al, (20) Crespo et al, (21) Gill et al, (22) and Lai et al (23) When selecting a patient to receive a shortened course of LDV/SOF, it is imperative for the clinician to assess if the patient may have a lower likelihood of SVR. Therefore, we investigated baseline patient and virologic characteristics that were associated with relapse.…”

Section: Discussionmentioning

confidence: 99%

“…The I 2 for heterogeneity was 0%, indicating no heterogeneity. Egger's regression testing did not reveal (13) Buggisch et al (20) Afdhal et al* (12) Gill et al (22) Lai et al (23) Crespo et al (21) Table S6). Subgroup analysis revealed similar RRs for relapse when evaluating studies incorporating patients with cirrhosis (RR 5 0.99, 95% CI 0.98-1.00) and without cirrhosis (RR 5 0.99, 95% CI 0.96-1.01).…”

Section: Meta-analysismentioning

confidence: 98%

“…This led to selection of six studies for inclusion, of which one was a published manuscript and the remainder were published abstracts. (12,13,(20)(21)(22)(23) A total of 5,637 cases were identified, with the study sample size varying from 90 to 1,981 patients. Details regarding the selected studies are outlined in Table 5.…”

Section: Meta-analysismentioning

confidence: 99%

See 4 more Smart Citations

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Meta-analysismentioning

confidence: 98%

Section: Meta-analysismentioning

confidence: 99%

See 3 more Smart Citations

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection

et al. 2017

View full text Add to dashboard Cite

show abstract

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

Curry

Tapper

Bacon

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Retrospective analysis of hepatitis C infected patients treated through an integrated care model

Levin¹,

Dabirshahsahebi²,

Bauer³

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo determine if our health system’s integrated model reflects sustained virologic response (SVR) outcomes similar to those in clinical trial data, maximizes adherence, and averts drug interactions.METHODSSubjects with chronic hepatitis C had their medical records reviewed from November 1st, 2014 through March 1st, 2016. Patients eligible for treatment were entered into an integrated care model therapy algorithm. The primary outcome was SVR12 based on intention to treat (ITT) analysis. Inclusion criteria consisted of both treatment naïve and experienced patients over the age of 18 who were at least twelve weeks post-therapy completion with any genotype (GT) or METAVIR score. Secondary outcomes included adherence, adverse events, and number of drug interaction interventions.RESULTSAt the time of analysis, 133 patients had reached twelve weeks post therapy with ITT. In the ITT analysis 70 patients were GT 1a, 26 GT 1b, 23 could not be differentiated between GT 1a or 1b, 8 GT 2, 4 GT 3, and 2 patients with multiple genotypes. The ITT treatment regimens consisted of 97 sofosbuvir (SOF)/ledipasvir (LDV), 8 SOF/LDV and ribavirin (RBV), 7 SOF and Simeprevir (SMV), 6 3D and RBV, 1 3D, 11 SOF and RBV, and 1 SOF, peg interferon alpha, and RBV. The overall SVR12 rate was 93% in the ITT analysis with a total of 6 patients relapsing. In patients with cirrhosis, 89% obtained SVR12. All 33 patients who were previous treatment failures achieved SVR12. Drug-drug interactions were identified in 56.4% of our patient population, 69 of which required interventions made by the pharmacist. The most common side effects were fatigue (41.4%), headache (28.6%), nausea (18.1%), and diarrhea (8.3%). No serious adverse effects were reported.CONCLUSIONDean Health System’s integrated care model successfully managed patients being treated for hepatitis C virus (HCV). The integrated care model demonstrates high SVR rates amongst patients with different levels of fibrosis, genotypes, and HCV treatment history.

show abstract

Real-Word Effectiveness of 8, 12 and 24 Weeks Ledipasvir (LDV)/Sofosbuvir (SOF)-Based Therapy for Hepatitis C Virus (HCV) Genotype 1: Analysis in a Large Integrated Health Care System

Cited by 3 publications

References 0 publications

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

Retrospective analysis of hepatitis C infected patients treated through an integrated care model

Contact Info

Product

Resources

About